What is Alstem?
Alstem operates at the intersection of advanced biotechnology and precision research, providing a comprehensive suite of services that includes induced pluripotent stem cell (iPSC) generation, sophisticated gene editing, and high-efficiency virus packaging. By integrating proprietary tools such as HiBiT, HaloTag, NanoLuc, and NanoBiT, the company enables researchers to achieve unprecedented levels of accuracy in protein analysis. This technical infrastructure positions Alstem as a critical partner for academic and commercial laboratories seeking to accelerate discovery timelines through reliable, high-quality custom cell line generation and molecular biology solutions.
How much funding has Alstem raised?
Alstem has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Alstem
PPP
Public-Private Partnership
What's next for Alstem?
Following this late-stage funding round, Alstem is well-positioned to transition into a phase of aggressive market expansion and technological refinement. The strategic allocation of this capital will likely focus on scaling production capacity to meet the rising demand for iPSC-based research models and enhancing the throughput of their gene-editing platforms. As the biotechnology landscape shifts toward more personalized and precise therapeutic development, Alstem's commitment to rapid turnaround and high-fidelity research tools provides a robust foundation for sustained growth. Future initiatives will likely prioritize the commercialization of their existing toolset while exploring new frontiers in cellular engineering to maintain their competitive edge in the life sciences ecosystem.
See full Alstem company page
